WO2000053734A3 - Menschliche angiogeneserelevante nukleinsäure- und protein-sequenzen aus endothelzellen - Google Patents

Menschliche angiogeneserelevante nukleinsäure- und protein-sequenzen aus endothelzellen Download PDF

Info

Publication number
WO2000053734A3
WO2000053734A3 PCT/EP2000/002005 EP0002005W WO0053734A3 WO 2000053734 A3 WO2000053734 A3 WO 2000053734A3 EP 0002005 W EP0002005 W EP 0002005W WO 0053734 A3 WO0053734 A3 WO 0053734A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
endothelial cells
protein sequences
sequences obtained
relevant nucleic
Prior art date
Application number
PCT/EP2000/002005
Other languages
English (en)
French (fr)
Other versions
WO2000053734A2 (de
Inventor
Karl-Heinz Thierauch
Jens Glienke
Bernd Hinzmann
Christian Pilarsky
Original Assignee
Schering Ag
Thierauch Karl Heinz
Jens Glienke
Bernd Hinzmann
Christian Pilarsky
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19911684A external-priority patent/DE19911684A1/de
Priority claimed from DE19948679A external-priority patent/DE19948679A1/de
Application filed by Schering Ag, Thierauch Karl Heinz, Jens Glienke, Bernd Hinzmann, Christian Pilarsky filed Critical Schering Ag
Priority to AU31655/00A priority Critical patent/AU3165500A/en
Priority to EP00909340A priority patent/EP1144606A2/de
Priority to JP2000603357A priority patent/JP2002537832A/ja
Publication of WO2000053734A2 publication Critical patent/WO2000053734A2/de
Publication of WO2000053734A3 publication Critical patent/WO2000053734A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)

Abstract

Es werden Nukleinsäure-Sequenzen - mRNA, cDNA, genomische Sequenzen - aus Gewebe menschlicher Endothelzellen, die für Genprodukte oder Teile davon kodieren und deren Verwendung, beschrieben. Es werden weiterhin die über die Sequenzen erhältlichen Polypeptide und deren Verwendung beschrieben.
PCT/EP2000/002005 1999-03-09 2000-03-08 Menschliche angiogeneserelevante nukleinsäure- und protein-sequenzen aus endothelzellen WO2000053734A2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU31655/00A AU3165500A (en) 1999-03-09 2000-03-08 Human nucleic acid and protein sequences obtained from endothelial cells
EP00909340A EP1144606A2 (de) 1999-03-09 2000-03-08 Menschliche angiogeneserelevante nukleinsäure- und protein-sequenzen aus endothelzellen
JP2000603357A JP2002537832A (ja) 1999-03-09 2000-03-08 内皮細胞由来のヒト核酸配列及びタンパク質配列

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19911684.9 1999-03-09
DE19911684A DE19911684A1 (de) 1999-03-09 1999-03-09 Menschliche Nukleinsäure-Sequenzen aus Endothelzellen
DE19948679.4 1999-10-01
DE19948679A DE19948679A1 (de) 1999-10-01 1999-10-01 Nukleinsäuren und Protein-Sequenzen aus Endothelzellen

Publications (2)

Publication Number Publication Date
WO2000053734A2 WO2000053734A2 (de) 2000-09-14
WO2000053734A3 true WO2000053734A3 (de) 2001-04-26

Family

ID=26052387

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/002005 WO2000053734A2 (de) 1999-03-09 2000-03-08 Menschliche angiogeneserelevante nukleinsäure- und protein-sequenzen aus endothelzellen

Country Status (4)

Country Link
EP (1) EP1144606A2 (de)
JP (1) JP2002537832A (de)
AU (1) AU3165500A (de)
WO (1) WO2000053734A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ434899A0 (en) * 1999-11-26 1999-12-23 University Of Queensland, The Novel polynucleotide and polypeptide

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993016178A2 (en) * 1992-02-12 1993-08-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sequences characteristic of human gene transcription product
WO1996040769A1 (en) * 1995-06-07 1996-12-19 Progenitor, Inc. Developmentally-regulated endothelial cell locus-1
WO1998033916A2 (en) * 1997-01-31 1998-08-06 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993016178A2 (en) * 1992-02-12 1993-08-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sequences characteristic of human gene transcription product
WO1996040769A1 (en) * 1995-06-07 1996-12-19 Progenitor, Inc. Developmentally-regulated endothelial cell locus-1
WO1998033916A2 (en) * 1997-01-31 1998-08-06 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EMBL Datenbank, Heidelberg, FRG Emest_Hum1 Eintrag No. AA605117 30. September 1997 NCI-CGAP: "no71b07.s1 NCI_CGAP_AA1 Homo sapiens cDNA clone IMAGE:1112245 3', mRNA sequence" *
EMBL Datenbank, Heidelberg, FRG Emhum5 Eintrag No. AL050367 27. Mai 1999 WAMBUTT, R. ET AL.: "Homo sapiens mRNA; cDNA DKFZp564A026" *
KENDALL, R.L. & THOMAS, K.A.: "Inhibition of vascular endothelial cell growth factor by an endogenously encoded soluble receptor", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 90, no. 22, 15 November 1993 (1993-11-15), pages 10705 - 10709, XP002146190 *
PRÖLS, F. ET AL.: "Differential Expression of Osteopontin, PC4, and CEC5, a Novel mRNA Species, during in vitro Angiogenesis", EXPERIMENTAL CELL RESEARCH, vol. 239, no. 1, 25 February 1998 (1998-02-25), pages 1 - 10, XP000925893 *

Also Published As

Publication number Publication date
JP2002537832A (ja) 2002-11-12
WO2000053734A2 (de) 2000-09-14
AU3165500A (en) 2000-09-28
EP1144606A2 (de) 2001-10-17

Similar Documents

Publication Publication Date Title
WO1999053040A3 (de) Menschliche nukleinsäuresequenzen aus ovartumorgewebe
WO1999054461A3 (de) Menschliche nukleinsäuresequenzen aus endometriumtumorgewebe
WO1999038972A9 (en) Human genes and gene expression products ii
WO1999047669A3 (de) Menschliche nukleinsäuresequenzen aus brusttumorgewebe
WO1999055858A3 (de) Menschliche nukleinsäuresequenzen aus pankreastumorgewebe
WO1999058675A3 (en) Human genes and gene expression products v
WO2002014500A3 (en) Human genes and gene expression products
ATE418563T1 (de) Nik proteine, nukleinsäure sowie verfahren
WO2001066753A3 (en) Human genes and gene expression products
WO2003020932A1 (fr) Nouvelles proteines de secretion et adn associe
WO2001005825A3 (en) Nucleic acid sequences encoding putative angiopoietin proteins
JP2002535956A5 (de)
WO1999051727A3 (de) Menschliche nukleinsäuresequenzen aus ovarnormalgewebe
WO2001068854A3 (en) Fibroblast growth factor-like molecules and uses thereof
WO2000053776A3 (en) Human kallikrein-like genes
WO2004007664A3 (en) Nucleic acid vectors
WO2002070549A3 (en) Chimeric polypeptides of serum albumin and uses related thereto
WO1999046374A3 (de) Menschliche nukleinsäuresequenzen aus prostatatumorgewebe
WO1999054353A3 (de) Menschliche nukleinsäuresequenzen aus uterusnormalgewebe
WO1999054447A3 (de) Menschliche nukleinsäuresequenzen aus blasentumorgewebe
WO1999047655A3 (de) Menschliche nukleinsaeurefragmente, deren expression in brustnormalgewebe erhöht ist
WO1999046375A3 (de) Menschliche nukleinsäuresequenzen aus prostatagewebe
WO2000053734A3 (de) Menschliche angiogeneserelevante nukleinsäure- und protein-sequenzen aus endothelzellen
WO2003000896A3 (en) POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNα-5 GENE
WO2000041509A3 (en) Polypeptides having acid phosphatase activity and nucleic acids encoding same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000909340

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 603357

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2000909340

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09936133

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2000909340

Country of ref document: EP